News
We send the latest information from SMC Laboratories.
Reserve a non-clinical pharmacology consultation with us at BIO KOREA 2022!
We will join BIO KOREA 2022 International Convention, one of the biggest bio-health conventions in Asia. BIO KOREA 2022 offers business and global partnership opportunities for executives from pharmaceutical/biotechnology companies through business forums, exhibition, conference, and investment fair. We would love to have the opportunity to meet with you virtually and introduce…
kk
We would like to introduce a study published by our client using our proprietary non-alcoholic steatohepatitis (NASH) model called STAMTM (Ikewaki et al., bioRxiv, 2021). In this study, the authors evaluated how the single or combined consumption of two beta-glucans derived from the AFO-202 and N-163 strains of black yeast, Aureobasidium pullulans, affected the…
Introduction of the paper using our UUO model
We would like to introduce a paper published by our client using Chronic kidney disease model. In this paper, the authors showed improvement of the disease state and analyzed the mechanism of UUO-induced kidney fibrosis model by histological analysis and gene expression analysis after the administration of compounds. About the UUO…
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunction-associated fatty liver disease is a new concept in the understanding of fatty liver disease and it’s pathogenesis. A consensus statement on this disease concept was published in the Journal of Hepatology in 2020. For…
Drug efficacy studies using multiple mouse models to replicate human disease.
To date, numerous clinical trials have been conducted using existing and newly developed drugs in the field of NASH. However, no therapeutic medications for NASH have yet been launched. One of the reasons is the lack of animal models that can completely reproduce the pathology of NASH as seen in humans due to the…
The comparison of NASH-HCC and other HCC models
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020. Among them, hepatocellular carcinoma (HCC) is known to account for about 90% of all liver cancers. Hepatitis B and C, alcohol, and diabetes are known to cause HCC, but NAFLD/NASH has been…
Drug efficacy study in NASH mouse model
We would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) model. (Murakami et al., Cells., 2022). In this paper, the authors evaluated the effect of pemafibrate, a selective PPARα modulator, and tofogliflozin, an inhibitor of Na+/glucose-conjugated transport carrier 2, alone and in combination on the progression of NASH…
Published papers with IPF model
We would like to share with you some examples of studies that our clients have often asked us about using the IPF model. CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology company developing mitochondria-based therapeutics also announced interesting data with our IPF model at the American Thoracic Society’s Virtual 2020 Conference. The ePoster presents…
Why is Chronic Kidney Disease so hard to research?
Between 9 – 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, how can we develop more effective therapies for this underserved population? –What is chronic kidney disease? CKD is a persistent loss of kidney function and structural abnormalities that are assessed using markers of kidney damage and histological…
What is proteinuria’s role in evaluating the progression of CKD?
When discussing our mouse models for chronic kidney disease (CKD), we are often asked about proteinuria as a urinary marker of kidney damage. As an important marker used in clinical trials, it's also an important endpoint to look at in non-clinical research as well. Proteinuria data in the Adriamycin model The graph above shows…